发明授权
US07745459B2 Quinolizinone compound and use thereof as HIV integrase inhibitor
有权
喹诺酮酮化合物及其作为HIV整合酶抑制剂的用途
- 专利标题： Quinolizinone compound and use thereof as HIV integrase inhibitor
- 专利标题（中）： 喹诺酮酮化合物及其作为HIV整合酶抑制剂的用途
-
申请号： US11230330申请日： 2005-09-20
-
公开(公告)号： US07745459B2公开(公告)日： 2010-06-29
- 发明人: Motohide Satoh , Hisateru Aramaki , Hiroshi Nakamura , Masafumi Inoue , Hiroshi Kawakami , Hisashi Shinkai , Yuji Matsuzaki , Kazunobu Yamataka
- 申请人： Motohide Satoh , Hisateru Aramaki , Hiroshi Nakamura , Masafumi Inoue , Hiroshi Kawakami , Hisashi Shinkai , Yuji Matsuzaki , Kazunobu Yamataka
- 申请人地址： JP Tokyo
- 专利权人： Japan Tobacco Inc.
- 当前专利权人： Japan Tobacco Inc.
- 当前专利权人地址： JP Tokyo
- 代理机构： Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
- 优先权： JP2004-272820 20040921; JP2005-234884 20050812
- 主分类号： A01N43/90
- IPC分类号： A01N43/90 ; A61K31/44 ; C07D455/02
摘要：
A pharmaceutical agent having an anti-HIV action, particularly, a pharmaceutical agent having an integrase inhibitory action, is provided.The present invention relates to a quinolizinone compound represented by the following formula [I] wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and an anti-HIV agent containing same as an active ingredient. The compound of the present invention has an HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compounds can become a more effective anti-HIV agent. Since the compound has a high inhibitory activity specific for integrases, the compound can provide a safe pharmaceutical agent for human with a fewer side effects.